The interaction of antimicrobial peptide LL-37 with artificial biomembranes: epifluorescence and impedance spectroscopy approach
暂无分享,去创建一个
[1] M. Enright. The evolution of a resistant pathogen--the case of MRSA. , 2003, Current opinion in pharmacology.
[2] Z. Figaszewski,et al. Impedance analysis of phosphatidylcholine membranes modified with gramicidin D. , 2003, Bioelectrochemistry.
[3] I. Kubo,et al. Molecular design of multifunctional antibacterial agents against methicillin resistant Staphylococcus aureus (MRSA). , 2003, Bioorganic & medicinal chemistry.
[4] M. Borg. Bed occupancy and overcrowding as determinant factors in the incidence of MRSA infections within general ward settings. , 2003, The Journal of hospital infection.
[5] Dong-Kuk Lee,et al. Mechanism of lipid bilayer disruption by the human antimicrobial peptide, LL-37. , 2003, Biochemistry.
[6] Oleg Konovalov,et al. Interaction of antimicrobial peptide protegrin with biomembranes , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[7] James M. Wilson,et al. Cathelicidins - a family of multifunctional antimicrobial peptides , 2003, Cellular and Molecular Life Sciences CMLS.
[8] J. Prous,et al. Gateways to clinical trials. March 2003. , 2003, Methods and findings in experimental and clinical pharmacology.
[9] Niv Papo,et al. Exploring peptide membrane interaction using surface plasmon resonance: differentiation between pore formation versus membrane disruption by lytic peptides. , 2003, Biochemistry.
[10] Paul Geladi,et al. Gramicidin A interaction at a dioleoyl phosphatidylcholine monolayer on a mercury drop electrode , 2003, Analytical and bioanalytical chemistry.
[11] Göran Carlsson,et al. Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study , 2002, The Lancet.
[12] J. Prous,et al. Gateways to Clinical Trials. June 2002. , 2002, Methods and findings in experimental and clinical pharmacology.
[13] Balaji Ramanathan,et al. Cathelicidins: microbicidal activity, mechanisms of action, and roles in innate immunity. , 2002, Microbes and infection.
[14] M. Zasloff. Antimicrobial peptides of multicellular organisms , 2002, Nature.
[15] P. Leeson,et al. Iseganan hydrochloride: Treatment of mucositis, treatment of cystic fibrosis, antibiotic , 2002 .
[16] Alshakim Nelson. Conducting gramicidin channel activity in phospholipid monolayers. , 2001, Biophysical journal.
[17] E. Greenberg,et al. Bactericidal Activity of Mammalian Cathelicidin-Derived Peptides , 2000, Infection and Immunity.
[18] Y. Shai,et al. Structure and organization of the human antimicrobial peptide LL-37 in phospholipid membranes: relevance to the molecular basis for its non-cell-selective activity. , 1999, The Biochemical journal.
[19] H. Mcconnell,et al. Red Blood Cell Lipids Form Immiscible Liquids , 1998 .
[20] A. Nelson,et al. Impedance measurements with phospholipid-coated mercury electrodes , 1998 .
[21] D. Andreu,et al. Animal antimicrobial peptides: an overview. , 1998, Biopolymers.
[22] J. Zasadzinski,et al. DESIGN AND PERFORMANCE OF AN INTEGRATED FLUORESCENCE, POLARIZED FLUORESCENCE, AND BREWSTER ANGLE MICROSCOPE/LANGMUIR TROUGH ASSEMBLY FOR THE STUDY OF LUNG SURFACTANT MONOLAYERS , 1997 .
[23] Y. Shai,et al. Aggregation and organization of pardaxin in phospholipid membranes. A fluorescence energy transfer study. , 1992, The Journal of biological chemistry.
[24] A. Nelson. Electrochemical studies of thallium(I) transport across gramicidin modified electrode-adsorbed phospholipid monolayers , 1991 .
[25] A. Nelson,et al. Phospholipid Monolayers At The Mercury Water Interface , 1986 .
[26] B. Roelofsen,et al. Relation between various phospholipase actions on human red cell membranes and the interfacial phospholipid pressure in monolayers. , 1975, Biochimica et biophysica acta.